GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhongyuan Union Cell & Gene Engineering Corp Ltd (SHSE:600645) » Definitions » Net Current Asset Value

Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Net Current Asset Value : ¥1.84 (As of Mar. 2025)


View and export this data going back to 1993. Start your Free Trial

What is Zhongyuan Union Cell & Gene Engineering Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Zhongyuan Union Cell & Gene Engineering's net current asset value per share for the quarter that ended in Mar. 2025 was ¥1.84.

The historical rank and industry rank for Zhongyuan Union Cell & Gene Engineering's Net Current Asset Value or its related term are showing as below:

SHSE:600645' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.82   Med: 18.99   Max: 184.51
Current: 12.24

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Zhongyuan Union Cell & Gene Engineering was 184.51. The lowest was 9.82. And the median was 18.99.

SHSE:600645's Price-to-Net-Current-Asset-Value is ranked worse than
81.5% of 984 companies
in the Biotechnology industry
Industry Median: 3.855 vs SHSE:600645: 12.24

Zhongyuan Union Cell & Gene Engineering Net Current Asset Value Historical Data

The historical data trend for Zhongyuan Union Cell & Gene Engineering's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongyuan Union Cell & Gene Engineering Net Current Asset Value Chart

Zhongyuan Union Cell & Gene Engineering Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 0.98 1.24 1.67 1.71

Zhongyuan Union Cell & Gene Engineering Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 1.59 1.69 1.71 1.84

Competitive Comparison of Zhongyuan Union Cell & Gene Engineering's Net Current Asset Value

For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhongyuan Union Cell & Gene Engineering's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's Price-to-Net-Current-Asset-Value falls into.


;
;

Zhongyuan Union Cell & Gene Engineering Net Current Asset Value Calculation

Zhongyuan Union Cell & Gene Engineering's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(2456.314-1589.881-63.978-0)/467.949
=1.71

Zhongyuan Union Cell & Gene Engineering's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(2488.024-1566.092-61.502-0)/467.949
=1.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhongyuan Union Cell & Gene Engineering  (SHSE:600645) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Zhongyuan Union Cell & Gene Engineering Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Zhongyuan Union Cell & Gene Engineering's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhongyuan Union Cell & Gene Engineering Business Description

Traded in Other Exchanges
N/A
Address
45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
Executives
Li De Fu Director
Wang Xue Jun senior management
Wang Yong Director
Li Hai Bin Director
He Wei senior management
Li Qiang senior management
Wu Ming Yuan Director
Wang Hui Director
Huang Jia Xue senior management
Cao Hai Feng Director
Han Yue E Director
Liu Yong Jun senior management
Cui Jing Xue Supervisors
Yang Guang Xing senior management
Meng Zhi Hong senior management

Zhongyuan Union Cell & Gene Engineering Headlines

No Headlines